<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466087</url>
  </required_header>
  <id_info>
    <org_study_id>M15-337</org_study_id>
    <nct_id>NCT02466087</nct_id>
  </id_info>
  <brief_title>Role of Magnesium Supplementation in the Treatment of Depression</brief_title>
  <official_title>Role of Magnesium Supplementation in the Treatment of Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to test the hypothesis that magnesium supplementation will
      decrease depressive symptoms in adults.

      This study takes place over 12 consecutive weeks. While the investigators will follow the
      volunteers for the full 12 weeks volunteers will only take magnesium supplements for 6
      consecutive weeks. Volunteers will be randomly assigned to start the supplement at week 1 or
      week 7. Volunteers will take two supplement two times a day for a total of 248 mg elemental
      magnesium daily in the form of magnesium chloride. This amount of magnesium is less than the
      tolerable upper limit of 350 mg per day. The supplements will be provided. Volunteers will be
      asked to maintain their normal diet for the 12 weeks of the study.

      The primary outcome measure is the PHQ-9 questionnaire, a validated measure of depression.
      Secondary measures include the GAD-7 for Anxiety and side effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Health Questionnaire-9</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in score from week 1 to week 6 and week 7 to week 12 (difference in differences)
The Patient Health Questionnaire-9 Item is a validated questionnaire with high sensitivity and specificity for the diagnosis of depression. The PHQ-9 score can range from 0 to 27, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-19 Moderate to Severe; 20-27 Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder 7 Item Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in score from week 1 to week 6 and week 7 to 12 (difference in differences)
GAD-7 score has been shown to be a valid indication of anxiety symptoms. The GAD-7 score can range from 0 to 21, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-21 Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Headaches While Taking Supplements</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in headaches compared to normal during the 6 weeks on supplements. Change was calculated from 2 time points-start of supplements and end of supplements.
Change was recorded as 0, None (same)
Mild
Moderate
Severe (worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Mg Cl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg Mg Cl per day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mg Cl</intervention_name>
    <description>Four supplements a day for 6 weeks.</description>
    <arm_group_label>Mg Cl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adults at least 18 years of age

          -  A Patient Health Questionnaire-9 (PHQ-9) score of greater or equal to 5 but less than
             20

          -  People who are currently being treated for depression are still eligible to
             participate but their treatment must be stable (no changes in medication dose or brand
             and/or no changes in therapy regimen for at least 2 months).

        Exclusion Criteria:

          -  Active delirium or dementia

          -  Medicinal treatment for bipolar disorder, personality disorder or schizophrenia,

          -  Glomerular Filtration Rate of less than 60

          -  Irritable Bowel Disease

          -  Inflammatory Bowel Disease

          -  GERD

          -  Gastritis

          -  Pregnant as reported by potential volunteer

          -  Myasthenia Gravis

          -  Planned elective surgery

          -  Currently taking

               -  Long Term Antibiotics

               -  Fluoroquinolone

               -  Trientine or Penicillamine

               -  Long Term Antivirals

               -  Digoxin

               -  Bisphosphonates

               -  Eltrombopag

               -  Opiods

               -  Calcium Channel Blockers

               -  Deferiprone

               -  Doxercalciferol

          -  Unable or unwilling to stop taking a magnesium supplement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Tarleton, MS, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <results_first_submitted>June 29, 2017</results_first_submitted>
  <results_first_submitted_qc>April 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2019</results_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Emily Tarleton</investigator_full_name>
    <investigator_title>Bionutrition Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02466087/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02466087/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mg Cl (Weeks 1-6), Then no Intervention (Weeks 7-12)</title>
          <description>MgCl for weeks 1-6 and then no treatment for weeks 7-12</description>
        </group>
        <group group_id="P2">
          <title>No Intervention (Weeks 1-6), Then MgCl (Weeks 7-12)</title>
          <description>No Treatment for weeks 1-6 and then MgCl for weeks 7-12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention: Weeks 1-6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention: Weeks 7-12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive MgCl first and no intervention first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Numbers represent participants with analyzable data.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Numbers reflect participants with analyzable data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Health Questionnaire-9</title>
        <description>Change in score from week 1 to week 6 and week 7 to week 12 (difference in differences)
The Patient Health Questionnaire-9 Item is a validated questionnaire with high sensitivity and specificity for the diagnosis of depression. The PHQ-9 score can range from 0 to 27, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-19 Moderate to Severe; 20-27 Severe.</description>
        <time_frame>12 weeks</time_frame>
        <population>Number of participants with analyzable data.</population>
        <group_list>
          <group group_id="O1">
            <title>MgCl</title>
            <description>6 weeks of MgCl supplements</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>6 weeks of no supplements</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Health Questionnaire-9</title>
          <description>Change in score from week 1 to week 6 and week 7 to week 12 (difference in differences)
The Patient Health Questionnaire-9 Item is a validated questionnaire with high sensitivity and specificity for the diagnosis of depression. The PHQ-9 score can range from 0 to 27, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-19 Moderate to Severe; 20-27 Severe.</description>
          <population>Number of participants with analyzable data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.28" lower_limit="-4.99" upper_limit="-3.56"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-0.90" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>diiference in differences</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Generalized Anxiety Disorder 7 Item Questionnaire</title>
        <description>Change in score from week 1 to week 6 and week 7 to 12 (difference in differences)
GAD-7 score has been shown to be a valid indication of anxiety symptoms. The GAD-7 score can range from 0 to 21, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-21 Severe.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MgCl</title>
            <description>6 weeks of MgCl supplementation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>6 weeks of no supplements</description>
          </group>
        </group_list>
        <measure>
          <title>Generalized Anxiety Disorder 7 Item Questionnaire</title>
          <description>Change in score from week 1 to week 6 and week 7 to 12 (difference in differences)
GAD-7 score has been shown to be a valid indication of anxiety symptoms. The GAD-7 score can range from 0 to 21, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-21 Severe.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.88" lower_limit="-4.70" upper_limit="-3.07"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.02" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Headaches While Taking Supplements</title>
        <description>Change in headaches compared to normal during the 6 weeks on supplements. Change was calculated from 2 time points-start of supplements and end of supplements.
Change was recorded as 0, None (same)
Mild
Moderate
Severe (worse)</description>
        <time_frame>12 weeks</time_frame>
        <population>headaches</population>
        <group_list>
          <group group_id="O1">
            <title>MgCl</title>
            <description>6 weeks of MgCl supplements</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>6 weeks of no supplements</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Headaches While Taking Supplements</title>
          <description>Change in headaches compared to normal during the 6 weeks on supplements. Change was calculated from 2 time points-start of supplements and end of supplements.
Change was recorded as 0, None (same)
Mild
Moderate
Severe (worse)</description>
          <population>headaches</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" lower_limit="-0.25" upper_limit="-0.03"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.25" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mg Supplementation</title>
          <description>6 weeks of Mg Supplements</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>6 weeks of no MgCl supplements</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emily Tarleton, MS, RD</name_or_title>
      <organization>University of Vermont</organization>
      <phone>802-847-4730</phone>
      <email>emily.tarleton@uvm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

